Drug Development Research, volume 84, issue 8, pages 1595-1623

Pyridazine derivatives as selective COX‐2 inhibitors: A review on recent updates

Publication typeJournal Article
Publication date2023-09-26
scimago Q2
SJR0.672
CiteScore6.4
Impact factor3.5
ISSN02724391, 10982299
PubMed ID:  37751330
Drug Discovery
Abstract

Selective cyclooxygenase (COX)‐2 inhibitors have several advantages over nonselective COX inhibitors (nonsteroidal anti‐inflammatory drugs [NSAIDs]), including the absence of adverse effects (renal and hepatic disorders) associated with the long‐term use of standard NSAIDs, as well as an improved gastrointestinal profile. The pyridazine nucleus is regarded as a promising scaffold for the development of powerful COX‐2 inhibitors, particularly when selectively functionalized. This article summarizes some methods for the synthesis of pyridazine derivatives. Furthermore, it covers all of the pyridazine derivatives that have appeared as selective COX‐2 inhibitors, making it useful as a reference for the rational design of novel selective COX‐2 inhibitors.

Found 
Found 

Top-30

Journals

1
2
1
2

Publishers

1
2
3
1
2
3
  • We do not take into account publications without a DOI.
  • Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Share
Cite this
GOST | RIS | BibTex | MLA
Found error?